Additional health benefits Beyond glycemic control and weight loss, GLP-1 RAs are linked to a number of cardiometabolic advantages
Shereef Elnahal said roughly $2 billion of the $6.6 billion requested from Congress is needed for weight-loss drugs known as glucagon-like peptide 1, or GLP-1, agonists, and new medications for illnesses found in veterans, such as metabolic dysfunction-associated steatohepatitis, or MASH, a fatty liver disease
Inositol has been shown to support fat loss, protect muscle, and improve insulin sensitivitymaking weight loss more sustainable
However, macrovascular benefit was elusive in people with T2D of longer duration (7.911.5 years) in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) and Veterans Affairs Diabetes Trial (VADT) studies [35, 36], and the Action to Control Cardiovascular Risk in Diabetes (ACCORD) study reported increased CV mortality [37]
These individuals are often referred to as nonresponders to the medication, meaning they do not lose at least 5% of their body weight after three months on semaglutide